An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Personalis to Participate in the 24th Annual Needham Virtual Growth Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Personalis, Inc. (NASDAQ: PSNL), a leader in cancer genomics, will present at the 24th Annual Needham Virtual Growth Conference on January 11, 2022. The company's innovative Personalis NeXT Platform® provides comprehensive genomic insights from tissue samples, aiding in precision oncology. Furthermore, Personalis is a key provider for Veterans Affairs' Million Veteran Program, reinforcing its position in population sequencing. The firm's lab emphasizes clinical accuracy with necessary certifications, ensuring top-tier service in advanced cancer diagnostics.
Positive
None.
Negative
None.
MENLO PARK, Calif.--(BUSINESS WIRE)--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 24th Annual Needham Virtual Growth Conference on Tuesday, January 11, 2022.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to Veterans Affairs' Million Veteran Program. To enable cancer and population sequencing, Personalis'Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit www.personalis.com and follow Personalis on LinkedIn and Twitter.
